UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008047
Receipt number R000009468
Scientific Title Effect of antispasmodic drug on endoscopic ultrasonography-a multicencer randomized comparative trial
Date of disclosure of the study information 2012/05/28
Last modified on 2013/11/22 17:39:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of antispasmodic drug on endoscopic ultrasonography-a multicencer randomized comparative trial

Acronym

Effect of antispasmodic drug on endoscopic ultrasonography-a multicencer randomized comparative trial

Scientific Title

Effect of antispasmodic drug on endoscopic ultrasonography-a multicencer randomized comparative trial

Scientific Title:Acronym

Effect of antispasmodic drug on endoscopic ultrasonography-a multicencer randomized comparative trial

Region

Japan


Condition

Condition

pancreatobiliary disease necessary for EUS or EUS-FNA

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the differece between EUS/EUS-FNA with and without antispasmodic drugs

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Total examination time

Key secondary outcomes

(1)Vital signs before, during and after EUS/EUS-FNA
(2)Dose of sedative drugs
(3)10 point VAS score for endoscopists and (4)patients satisfaction in EUS/EUS-FNA
(5)Number of puncture and rate of aquisition of specimen in EUS-FNA
(6)Dose of additive antispasmodic drugs


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Single blind -investigator(s) and assessor(s) are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

use of antispasmodic drugs

Interventions/Control_2

no use of antispasmodic drugs

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

(1)Patients aged 20 years and older
(2)Patients necessary for EUS/EUS-FNA
(3)Patients with informed consent for joining the present study

Key exclusion criteria

(1)Refusal to provide informed consent (2)Poor general status (performance status 4: completely disabled, cannot perform any self-care, and totally confined to the bed)
(3)Younger than age 20 years
(4)Incapability of insertion of echoendoscope
(5)Severe heart or pulmonary dysfunction (6)Pregnancy
(7)Use of antispasmodic drugs (within 12 h) before EUS/EUS-FNA
(8)Patients with bleeding tendency
(9)Patients with hemorrhagic colitis, glaucoma, benign prostat hyperplasia, paralytic ileus, pheocromocytoma or allergy for butylscoporamine or glucagon
(10)Judged inappropriate by a doctor

Target sample size

400


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaki Kuwatani

Organization

Hokkaido university hospital

Division name

Department of Gastroenterology

Zip code


Address

North14, West5, Kita-ku, Sapporo

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Hokkaido university hospital

Division name

Department of Gastroenterology

Zip code


Address


TEL


Homepage URL


Email

mkuwatan@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido university hospital

Institute

Department

Personal name



Funding Source

Organization

Hokkaido university hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 05 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 04 Month 27 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 01 Day

Last follow-up date

2013 Year 02 Month 13 Day

Date of closure to data entry

2013 Year 02 Month 13 Day

Date trial data considered complete

2013 Year 02 Month 28 Day

Date analysis concluded

2013 Year 11 Month 22 Day


Other

Other related information



Management information

Registered date

2012 Year 05 Month 28 Day

Last modified on

2013 Year 11 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009468


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name